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Abstract
Purpose The purpose of this study is to assess the
relationship between magnetic resonance images (MRI) of
the hypothalamic–pituitary (H-P) region and response to
recombinant human growth hormone (rhGH) treatment in
short children with growth hormone deficiency, basing on
changes of auxologic parameters, as well as to answer the
question if MRI may serve for selecting and monitoring the
rhGH responders.
Patients and methods The study group comprised 85
children treated with rhGH, aged 7.3–18.7 years, followed
for the mean period of 3.2 years (range, 2.1–9.5 years).
Auxologic parameters (height deficit hSDS, deviation from
the mid-parental height hSDS–mpSDS, bone delay index
bone age/chronological age ratio (BA/CA)) were assessed
before, during and at the end of rhGH treatment; growth
velocity was calculated before and during rhGH therapy.
Parameters were correlated with the MRI of the H-P region.
Results Structural anomalies of the H-P region were found
in 22 (25.9%) children: empty sella syndrome (ESS) in 12
(14.1%) patients, ectopic posterior pituitary (EPP) in ten
(11.8%). Patients’ height deficit and their deviation from
parental height before rhGH therapy was significantly
greater in the EPP group (median hSDS=−3.8; hSDS–
mpSDS=−2.5), bone age delay was the greatest in the ESS
group (median BA/CA=0.69), after therapy – in the EPP
group (median BA/CA=0.82). Growth velocity improved
in the first year of the rhGH therapy in all groups; however,
the most significant acceleration was observed in the EPP
group (median delta hSDS=0.9), then stabilised and was
comparable in all groups.
Conclusions MRI may be helpful in predicting response to
the rhGH treatment, providing midline abnormalities are
taken into account.
Keywords Growth hormone deficiency.Magnetic
resonance.Ectopic posterior pituitary.Empty sella
syndrome.Recombinant growth hormone therapy.
Children
Introduction
Treating short children with recombinant human growth
hormone (rhGH) is an expensive and long-term modality,
hence it has been strived for selecting patients who would
benefit the most from such therapy. Minimal criteria for
diagnosing growth hormone deficiency (GHD) should
include auxologic and biochemical parameters [12]. How-
ever, laboratory assays tend to be imperfect due to low
reproducibility, intrapersonal and cyclic variability of
growth hormone (GH) secretion, hence auxology still
remains the most important diagnostic criterion [10, 12–
14, 23, 27]. It is believed that the greatest benefits of rhGH
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significant growth deficiency, slow height velocity and
delayed bone age [1, 12]. It has been suggested that limited
propagation of magnetic resonance imaging (MRI) of the
hypothalamic–pituitary (H-P) region is one of the reasons
for not achieving desirable treatment effects [12]. Magnetic
resonance is a choice method for visualising the pituitary
region, as it provides high contrast resolution, the possibility
of multiplanar imaging, omits artefacts from bone structures
and avoids X-ray exposure, being particularly advantageous
in children [8]. Usually, MRI is performed as an end-step
diagnostic procedure to exclude expansive lesions in the H-P
region before initiation of the rhGH treatment. However, it
can also be used to visualise congenital structural abnormal-
ities in the central nervous system, which may be associated
with growth disturbances. It has been postulated that MRI
may be a more accurate indicator of hormonal deficiencies
and potential response to the rhGH treatment than laboratory
results [6, 9, 17, 26].
Previously, we published that GH secretion did not
depend on the size of the pituitary, unless structural defects
of the H-P region are taken into account, which was also
supported by other reports [3, 15, 25]. The aim of the
present study was to assess the relationship between MRI
of the H-P region and response to rhGH treatment in GH-
deficient children, basing on changes of auxologic param-
eters during a long-term follow-up, as well as to answer the
question if MRI findings may serve for selecting and
monitoring the rhGH responders.
Patients and methods
The studied group comprised 85 children and adolescents
(59 boys and 29 girls), ranging from 7.3 to 18.7 years of
age at the referral (median age, 14.1 years). The patients
were followed in the Department of Paediatrics, Endocri-
nology and Diabetes of the Medical University of Silesia,
Katowice, Poland, for the mean observational period of
3.2 years (range, 2.1–9.5 years). Inclusion criteria were as
follows: short stature (height below 2 standard deviations
(SDs) from the population mean), slow height velocity
(below tenth centile) and GHD (peak GH concentration
below 10 ng/ml in two stimulation tests). The latter
included intravenous administration of insulin in the dosage
of 0.1 U/kg (Actrapid, NovoNordisk) and reaching hypogly-
caemic state (serum glucose concentration below 40 mg/dl)
and after oral administration of clonidine in the dosage of
0.15 mg/m
2 body surface (Iporel, Polfa). Concentrations of
GH were assayed using chemiluminescent immunometric
method (Immulite, Euro/DPC, Llanberis, UK).
Based on inclusion criteria, children were treated with
rhGH in the mean dose of 0.03 mg/kg/day (Genotropin,
Pfeizer). Appropriate substitution therapy was implemented
in the case of deficiency of other pituitary hormones. The
rhGH therapy was terminated when slow height velocity
was noted (less than 3 cm per year).
Exclusion criteria comprised chromosomal aberrations,
dysmorphic syndromes, bone dysplasia, children born small
for gestational age or with intrauterine growth retardation,
patients with chronic diseases, acquired growth hormone
deficiency, including post-traumatic or post-neoplastic
deficiencies.
Anthropometry
Anthropometric measurements, referred to national growth
charts [21], and evaluation of sexual development using
Tanner staging were performed every 6 months. The
following parameters were derived from anthropometric
measurements and assessed before, during and at the end of
rhGH treatment: a number of SDs for the height (hSDS),
change of hSDS in a year, and the difference of SDs
between child’s height and the mid-parental height
(hSDS–mpSDS).
Imaging procedures
The MRI of the H-P region was assessed by two
radiologists (KG, JB), unaware of the endocrine diagnosis.
The studies were performed using a 1-T scanner (Magne-
tom Impact, Siemens, Erlangen, Germany), with a head
coil, in the coronal and sagittal planes at the level of the
pituitary (slice thickness of 3 mm without gap). The sagittal
planes were positioned parallel to the midline on the pilot
scan in the coronal plane. SE/T1-weighted sequences were
used before and after intravenous administration of the
contrast agent (Magnevist, Schering), in the dosage of
0.1 ml/kg body mass. Parameters of the T1 sequence were
as follows: TE, 15 ms; TR, 490–500 ms; FOV, 172×
230 mm; flip angle (FA), 90°; matrix, 256×256. No patient
required anaesthesia.
Special attention was paid to the visualisation of the
pituitary stalk and to the presence of structural anomalies in
the H-P area like ectopic posterior pituitary, empty sella
syndrome and other midline anomalies. Radiological
features of the empty sella syndrome were identified when
the sella space was not filled by the pituitary gland
completely. Instead, it was occupied at least partially by
the cerebrospinal fluid (CSF), with herniation of the
suprasellar cisterns below the line of the sella diaphragm
(i.e. below the line between the upper margin of the sella
tuberculum and the upper part of the sella dorsum). Partial
empty sella syndrome was defined when less than half of
the sella was filled with CSF, and the pituitary height was
more than 2 mm. Total empty sella syndrome was
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CSF, and the pituitary height was equal or less than 2 mm
[7].
Other radiological techniques used in the study included
wrist and hand X-ray of a non-dominant side in the anterior–
posterior projection and the assessment of the bone age
according to Greulich–Pyle standards [11], evaluated every
12 months. Index of bone age delay was calculated from the
bone age to chronological age ratio (BA/CA) before, during
and at the end of rhGH treatment.
Statistical analysis
A database was prepared in the calculative sheet Excel v.
2007. Detection of outlying values was carried out using
the criterion of abs(X) > Q + 1.5 IQR; IQR indicating
interquartile range, Q-upper or lower quartile of distribution
of the random variable X. Normality of distribution was
checked using parametric Lilliefors test. Hypothesis of
homogeneity of the variance was verified by Bartlett
statistics. Comparative analysis of the groups for variables
of normal distribution was carried out using standard
ANOVA algorithm and the Student’st test. In the case of
non-Gaussian distribution and/or lack of homogeneity of
the variance, hypothesis equality of distributions among
subgroups was verified using rank non-parametric method
of ANOVA Kruskal–Wallis and the Mann–Whitney U test.
Comparative analysis of observed time changes was carried
out using Friedmann ANOVA test as well as the Wilcoxon
signed-rank test or the Student’st test. Results of the
analyses were considered significant when p level was
below 0.05.
Patients’ guardians and patients older than 16 years of
age signed informed consent for the diagnostic procedures
as well as for the rhGH treatment. The study was approved
by the Ethics Committee of the Medical University of
Silesia.
Results
The initial analysis showed no significant differences
between genders in the aspect of assessed parameters, thus
girls and boys were further evaluated as one group.
On the basis of MRI, three subgroups were designated:
(1) children with normal H-P area, NP (63 children,
74.1%); (2) empty sella syndrome, (ESS) (12 children,
14.1%; Fig. 1a, b); (3) ectopic posterior pituitary (EPP) (ten
children, 11.8%; Fig. 2a, b). When the interrupted or poorly
visualised pituitary stalk, pituitary hypoplasia and ectopy of
the pituitary co-existed, the latter determined affinity to the
EPP group. Structural abnormalities in the pituitary MRI in
total were found in 22 (25.9%) children. Additionally,
hypoplasia of the corpus callosum along with septum
pellucidum agenesis were visualised in one girl, and Arnold
Chiari I malformation was found in one boy.
Children in the ESS group were significantly younger
(median, 10.9 years; range, 6.9–15.4 years) in comparison
to NP children (median, 14.2 years; range, 7.7–18.7; p<
0.001) and the EPP group (median, 14.9 years; range, 7.0–
17.2 years; p=0.045), whereas the chronological age of two
latter groups was comparable (p=0.606). Most children
with structural abnormalities in the H-P area were either
prepubertal or in an early stage of puberty, whereas NP
children had already entered puberty.
Combined pituitary hormonal deficiency was diagnosed
in nine children: in five cases of EPP, three ESS and in one
case of NP.
Relations between auxologic parameters and structural
abnormalities of the hypothalamic–pituitary area
before rhGH therapy
Children with EPP were significantly shorter as compared
to children in the NP group (median hSDS, −3.8 vs −3.1,
respectively; p=0.049), whereas height between EPP and
Fig. 1 MRI of the partially
empty sella (circle), SE/T1, cor-
onary plane (a) and sagittal
plane (b)
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significantly.
Moreover, patients with EPP were characterized by the
greatest deviation from the mid-parental height, as com-
pared to two other groups. Median hSDS–mpSDS for the
EPP amounted to −2.5 vs −1.5 for ESS and −1.7 for NP.
Statistical differences were significant between EPP and NP
(p=0.028). After excluding outlying values, the ESS group
was characterized by the greatest dispersion of the
examined variable.
In contrast, bone delay index (BA/CA) was the lowest
among children with ESS, as compared to NP and EPP
(median BA/CAwas equal to 0.69; 0.82; 0.77, respectively);
however, the statistical significance was found only between
NP and ESS (p=0.037)
Relations between auxologic parameters and structural
abnormalities of the hypothalamic–pituitary area
after the first year of rhGH therapy
Analysis of patients’ height and their deviation from the
mid-parental height after the first year of rhGH therapy did
not show significant differences among examined groups.
In contrast, differences were observed while comparing
bone delay index, which was significantly lower in the EPP
and ESS (median BA/CA, 0.81; 0.74, respectively) as
compared to NP (0.87; p=0.042 and 0.001, respectively).
Relations between auxologic parameters and structural
abnormalities of the hypothalamic-pituitary area
after termination of rhGH therapy
After discontinuation of rhGH therapy, the bone age
remained the most delayed in the EPP group (BA/CA,
0.82), as compared to NP (0.89; p=0.006) and ESS (0.91;
p=0.029). Other auxologic parameters were comparable in
all groups.
Height velocity in relation to the pituitary MRI prior,
during and after GH therapy
Height velocity, expressed by a change of hSDS between
two time intervals (delta hSDS) did not differ significantly
among the groups before rhGH treatment. Children with
EPP showed a tendency to slower height velocity as
compared with the two remaining groups; however, without
statistical significance.
In contrast, during rhGH therapy the EPP group turned
to the greatest positive change of hSDS in comparison to
the NP and EPP groups (Table 1; Fig. 3). In the following
years, change of hSDS was comparable in all the groups.
Discussion
According to various reports, patients with GHD and
structural abnormalities in MRI of the H-P area differ from
subjects with normal image of the pituitary in terms of
auxologic parameters [6, 18, 24, 26]. Coutant et al. showed
that children with GHD and abnormal MRI of the H-P area
were shorter and younger at the referral [6]. Additionally,
Maghnie et al. found the bone age to be more delayed in
this group of patients [18]. Similarly, we observed differ-
ences in the studied groups, namely children with EPP were
shorter, whereas the ESS group manifested more delayed
bone age as compared to subjects with normal pituitary.
Moreover, the height of EPP patients showed the greatest
deviation from the mid-parental height as compared to the
two other groups. The latter finding may indicate that
growth in children with normal pituitary, as well as in
Fig. 2 MRI of the ectopic pos-
terior pituitary (arrow), SE/T1,
coronary plane (a) and sagittal
plane (b)
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influenced by familial components. Studies in the adult
population indicate that most cases of ESS are asymptom-
atic [7]. In contrast, children more often manifest hormonal
and growth disturbances [30]. Hence, it has been disputed if
radiological features of partially empty sella translate into
hormonal dysfunction of the H-P axis, or it is only a
temporary phenomenon and the small pituitary normalizes
its parameters in the course of time [18].
Analyzing bone age, we found that it advanced in the
slowest manner in the EPP group, indirectly prolonging the
growth process. Not until the sex hormone deficiency
becomes overt and yet not compensated, maturation of the
bone age may be relatively slow. In our study, combined
pituitary hormonal deficiency co-existed with structural
midline defects in eight out of nine cases. It may be
hypothesized that in the case of EPP, hormonal deficiencies
evolve gradually, depending on the degree of the connec-
tion between the hypothalamus and the pituitary. However,
Tauber et al. found that children with severe pituitary
hypoplasia and ectopic posterior lobe may present with
symptoms of GH deficiency as early as in the neonatal
period [24]. The degree of pituitary dysfunction may
depend on the localisation of the posterior lobe, namely
whether it is placed in the median eminence or along the
stalk [5]. Status of the vascular bed which takes part in
signalisation between the hypothalamus and the pituitary is
also relevant. Precise dynamic MRI examination using
contrast agents facilitates visualisation of potential pathol-
ogy in this domain [4, 19]. Unfortunately in our study, it
was not possible to discriminate the subgroups in terms of
exact localisation of the posterior lobe due to a small
number of subjects.
Height velocity may be considered as a marker of the
response to rhGH. Change of hSDS did not differ
significantly among the studied groups before the treat-
ment, which is justified by the fact that slow growth rate
was one of the inclusion criteria, common for all subjects.
Subsequently, height velocity improved in all patients
during the observational period. Most children achieved
height, which did not differ significantly from the familial
potential, fulfilling therapeutic goals in the whole cohort.
However, children with ectopy of the posterior pituitary
showed the greatest positive change of the hSDS value, as
observed in the first year of the treatment. It reflects the
most dynamic catch-up growth in this group of patients,
starting from the greatest height deficit in the reference to
peers and parents. Literature reports show strong correlation
between the height velocity in the first year of rhGH
treatment, particularly in the prepubertal period, and the
total increment of hSDS [20, 22]. Moreover, Zenaty et al.
showed that the presence of congenital abnormalities in the
H-P area on MRI was more important than the maximum
concentration GH to predict the growth response to rhGH
treatmentinprepubertalGH-deficientchildrenduringa3-year
observation [29]. In our study, most patients with abnormal
H-P image were prepubertal at the referral, in contrast to
children with normal pituitary. In connection with the above,
the former group would have the most rational chance to
optimize the final height.
Interesting findings come from Coutant et al. who did
not show any significant differences in height velocity
between children with idiopathic short stature and GH-
deficient patients, both groups treated with rhGH, providing
normal MRI of the pituitary was found [6]. Basing on these
findings, the authors hypothesised that short stature in the
latter group, at least in part, is conditioned by extra-
hormonal factors. It was observed that even patients with
severe GHD showed similar height velocity to the group
with so-called partial GHD, if the MRI of the pituitary was
normal. The more rapid height velocity was observed in
severe GHD, co-existing with structural abnormalities [6].
There are doubts if non-treated children with normal
pituitary image would be able to grow spontaneously, for
example at the time of puberty. Difficulties in answering
Fig. 3 Box plots presenting height velocity (delta hSDS) in the first
12 months of rGH treatment depending on the MRI of the H-P region.
NP normal pituitary, ESS empty sella syndrome, EPP ectopic posterior
pituitary. Asterisks represent outlying values
Table 1 Height velocity (delta hSDS) in the first 12 months of rGH
treatment depending on the MRI of the H-P region
Delta hSDS Median Range Mean SD
NP (n=63) 0.6 −1.1; 1.8 0.7 0.6
ESS (n=12) 0.5 −0.4; 1.6 0.7 0.6
EPP (n=10) 0.9 −0.1; 2.1 1.0 0.8
Significance levels for differences among the groups: 1 vs 2 p=0.578;
1v s3p=0.042; 2 vs 3 p=0.040
NP normal pituitary, ESS empty sella syndrome, EPP ectopic posterior
pituitary
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possibility to select a control group comprising children
with laboratory indicators of GHD, not submitted to rhGH
therapy.
It must be underlined, however, that not only midline
defects condition GH deficiency. Mutations POU1F1 and
PROP1, which result in combined pituitary hormonal
deficiency, present with various sizes of the pituitary, from
hypertrophy to aplasia [28]. In the case of GH1 mutations,
despite severe GH deficiency, the structure of the pituitary
MRI is usually normal, as there is functional but not
structural impairment of somatotropes [2]. Thus, it may be
assumed that MRI of the pituitary depends on the stage of
life when it is performed [16, 18].
Basing on the results of this study and assuming critical
point of view, it cannot be stated explicitly that structural
abnormalities of the H-P region conditions the final height.
However, the greatest catch-up growth in the essential first
year of rhGH therapy in the group with ectopic posterior
pituitary indicates the best responders and may even
influence titration of the rhGH dosage. However, this
hypothesis would demand further randomized studies.
Nevertheless, MRI constitutes an essential method in
diagnosing endocrine disturbances, including cases of
congenital aetiology. It also provides additional infor-
mation concerning response to the substitution therapy.
Dynamically improving MRI methods with tridimensional
acquisitions, determining the real size of the gland, and
dynamic studies with contrast agents may contribute to better
understanding the function of the hypothalamic–pituitary
axis.
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